Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumito ABNGM:LUMITO +1.23%18 3-Year ROIIC % is 176.13 as of Dec. 2025. GuruFocus rates NGM:LUMITO with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Lumito AB ranks better than 86.14% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Lumito AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 176.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Lumito AB's 3-Year ROIIC % or its related term are showing as below:
NGM:LUMITO's 3-Year ROIIC % is ranked better than 86.14% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.385
vs NGM:LUMITO: 176.13
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Lumito AB 3-Year ROIIC % Related Terms
Lumito AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Lumito AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:LUMITO vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Lumito AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumito AB 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumito AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Lumito AB's 3-Year ROIIC % falls into.
Lumito AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -41.885 (Dec. 2025) - -27.287 (Dec. 2022) )
/
( 77.99 (Dec. 2025) - 86.278 (Dec. 2022) )
=
-14.598
/
-8.288
=
176.13%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Lumito AB (NGM:LUMITO) has a 3-Year ROIIC % of 176.13 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Lumito AB and its competitors. According to the industry distribution chart, Lumito AB ranks #28 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 13.9%.
Is Lumito AB's 3-Year ROIIC % too high?
Lumito AB's current 3-Year ROIIC % is 176.13. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.39. Lumito AB's value of 176.13 is 45648.1% above this industry median. Based on the distribution chart, Lumito AB ranks #28 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Lumito AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Lumito AB's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumito AB ranks #28 out of 202 companies for 3-Year ROIIC %. This places Lumito AB in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.39. Lumito AB's value of 176.13 is 45648.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.39, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumito AB's current 3-Year ROIIC % of 176.13 is 45648.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Lumito AB and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumito AB's current 3-Year ROIIC % is 176.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumito AB stock overvalued right now?
Lumito AB (NGM:LUMITO) has a current 3-Year ROIIC % of 176.13. The current 3-Year ROIIC % is 176.13 and 45648.1% above the Medical Diagnostics & Research industry median of 0.39. Lumito AB's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Lumito AB (NGM:LUMITO), the current 3-Year ROIIC % is 176.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples. The company holds a broad patent portfolio of three patent families. Lumito's solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.
18GF Score
Get the complete analysis for NGM:LUMITO
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:LUMITO has been successfully added to your 
